Exosome technologies

Exosome therapy is a bold new concept, with  significant clinical and commercial opportunities

Why Exosomes?

Extracellular Vesicles (EVs) are nanosized particles(50-200nm) released naturally by cells. They are important effectors of cell communication. A key mechanism by which cell therapies work is via release and uptake of EVs.

Extracellular Vesicle properties:

  • they contain unique mix of molecular cargo (including miRNA, proteins, peptides, lipids) that underpin their biological effect
  • they have homing capabilities that allow them to travel to the site of injury or disease
  • their immunomodulatory properties helps normalise the immune system
  • being low/non-immunogenic, they are not rejected by the body
  • they have other bioactive properties based on parent cell e.g. angiogenesis, anti-fibrotic, regenerative, etc.
Exosome

VivaZome = Nature + Technology

VivaZome is leveraging the best that nature and technology has to offer:

Targeted Extracellular Vesicles (TEVs)
  • Cell Source is key; exploit unique cell attributes.
  • Multiple cells types screened based on their native biological function.
  • EV quantity and quality assessed.
  • Cell engineering and EVloading and targeting technologies to enhance function.
  • Cell Engineering for immortalisation.
Universal Manufacturing Process
  • Optimised, best-in-class technology.
  • Proprietary components to complement established technology from leading suppliers.
  • Proprietary cells for manufacture.
  • Underpinned by extensive characterisation, molecular cargo analysis, potency assays that link attributes to function and clinical targets.

Clinical Targets

Traumatic Brain Injury Program

  • Including Post-Traumatic Epilepsy (PTE)

5.3 million Americans are living with Traumatic Brain Injury at a cost of USD 76.5 billion per annum. In USA, approx 2.5 million people sustain a traumatic brain injury per year.

Stroke Program

  • Acute and Chronic Stroke

About 800,000 Americans each year suffer a stroke. it is the No. 4 cause of death in the USA. Among survivors, 70% cannot work as they did before, and about one-third need help with basic self-care. About $74 billion is spent per year in the US for stroke-related medical costs and disability.

Neurodegenerative Program

  • Tauopathies and other dementias

Dementia causes problems with memory, thinking and behaviour and is the 6th leading cause of death in the US, with 500,000 dying pa. Approx 5.3 million Americans have dementia. There is currently no treatment to cure or stop the progression.